Big news: our prices just got a lot lower. Shop now|New here? Get up to $200 in welcome perks, valid for 14 days. Claim offer now
US shipping INCLUDED on orders above $200
Research Insights

All content and product details on this site are for educational purposes only. Products are for in-vitro studies (performed outside the body) and not FDA-approved for medical use. Any introduction into humans or animals is prohibited by law.

PP-CAG: Mechanism and Research Findings

Nabiha Khalid
October 27, 2026
PP-CAG: Mechanism and Research Findings

Brief Overview/Summary

PP-CAG is a long-acting amylin analog studied in metabolic research. A summary of its structure, amylin and calcitonin receptor pharmacology, and published preclinical findings.

PP-CAG is a long-acting amylin analog — a synthetic, lipidated peptide designed to mimic amylin, a 37-amino-acid hormone produced by pancreatic beta-cells that is involved in glucose regulation and the control of food intake [1][2]. Published research has characterised PP-CAG as a non-selective agonist of amylin receptors and the calcitonin receptor, and has examined its effect on food intake in rodents [3][4].

This overview is limited to structural, receptor-pharmacology and preclinical (in vitro and animal) findings reported in peer-reviewed literature. PP-CAG is supplied for laboratory research use only and is not approved for human or veterinary use. No conclusions can be drawn regarding safety or effects in humans.

Mechanism of Action of PP-CAG Peptide

Amylin acts through multisubunit G protein-coupled receptors formed when a core receptor protein is co-expressed with a receptor activity-modifying protein (RAMP), giving rise to multiple amylin receptor subtypes [1]. In transfected cells, co-expression of RAMP1 or RAMP3 with the calcitonin receptor (CTR) produced specific amylin binding and amylin-responsive cAMP signalling, with two distinct receptor phenotypes [5].

Amylin acts principally in the circumventricular organs of the central nervous system [1]. Its effect on eating is a meal-size effect that promotes meal-ending satiation and appears to depend on a direct action in the area postrema, a region rich in amylin receptors; the signal is relayed through the nucleus of the solitary tract and the lateral parabrachial nucleus to hypothalamic areas [6].

Native amylin has a strong tendency to aggregate into amyloid fibrils. Aggregated islet amyloid polypeptide (an alternative name for amylin) has cytotoxic properties and forms the pancreatic islet amyloid deposits studied in diabetes research [2]. This propensity was a central challenge in designing a stable amylin analog, and an earlier analog, pramlintide, has a short half-life [3].

PP-CAG was selected through structure–activity work aimed at stability and long duration of action. Relative to human amylin, it carries the substitutions 14E, 17R, 25P, 28P, 29P and 37P, and it is lipidated at the N-terminus with a C20 fatty diacid protractor attached through a γ-glutamate linker [3].

Research Evidence

The receptor pharmacology of PP-CAG has been profiled across 25 endpoints of receptor binding, activation and regulation. It was compared with amylin receptor-selective and non-selective lipidated analogs, with pramlintide (amylin receptor-selective) and salmon calcitonin (non-selective), and with human calcitonin and rat amylin as prototypical selective agonists of the calcitonin receptor and amylin receptors. PP-CAG behaved as a non-selective agonist of amylin receptors and the calcitonin receptor, with a pharmacological profile distinct from each comparator [4].

The authors of that study note increasing evidence that targeting amylin receptors, which are heterodimers of the calcitonin receptor and RAMPs, influences body-weight regulation and may act additively with GLP-1 receptor agonism. They also note that agonists which can independently activate the calcitonin receptor may differ in efficacy, even though selective calcitonin receptor activation on its own does not appear to be efficacious [4].

In rats, a single administration of PP-CAG reduced food intake for up to 48–60 hours, and pharmacokinetic studies in Sprague Dawley rats reported a half-life of approximately 27 hours [3].

These findings sit within a broader preclinical literature on amylin. Amylin increases energy expenditure in rats, and it has been proposed to act as an adiposity signal: chronic infusion of amylin into the brain reduced body-weight gain and adiposity, whereas chronic infusion of an amylin receptor antagonist increased adiposity [6]. Amylin may also affect hedonic aspects of eating, including a reduction in the rewarding value of food [7].

Research Application

PP-CAG is used in research on amylin receptor and calcitonin receptor pharmacology, including how non-selective agonism compares with selective activation of amylin receptor subtypes or of the calcitonin receptor [4].

Because amylin and GLP-1 act through different receptors, amylin receptor agonism is studied as a partner for GLP-1 receptor agonism, with the potential for additive effects on food intake and energy balance in preclinical models [4][8].

Central sites of action are another focus. The area postrema and its connections to the nucleus of the solitary tract, lateral parabrachial nucleus and hypothalamus are studied as the pathway through which amylin and its analogs influence meal size [6].

Peptide engineering is a further application. The development of PP-CAG illustrates how substitutions that reduce the tendency to form fibrils can be combined with lipidation to produce a stable, long-acting analog of an aggregation-prone hormone [2][3].

Future Application

The complementary mechanisms of amylin receptor agonists and GLP-1 receptor agonists have made their combination an active area of metabolic research [4][8]. Open preclinical questions include how amylin receptor subtypes and the calcitonin receptor each contribute to the effects of non-selective agonists, how amylin's homeostatic and hedonic effects on eating are separated at the circuit level, and how long-acting analogs differ from native amylin in receptor regulation [1][4][7].

Research use statement. PP-CAG is an investigational compound. The material supplied by Power Peptides is intended for laboratory research use only and is not approved by the U.S. Food and Drug Administration for human or veterinary use. It is not a drug, food or cosmetic, and must not be used in humans or animals.

References

  1. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564–600. doi:10.1124/pr.115.010629 · PMID 26071095

  2. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91(3):795–826. doi:10.1152/physrev.00042.2009 · PMID 21742788

  3. Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, et al. J Med Chem. 2021;64(15):11183–11194. doi:10.1021/acs.jmedchem.1c00565 · PMID 34288673

  4. Fletcher MM, Keov P, Truong TT, Mennen G, Hick CA, Zhao P, et al. J Pharmacol Exp Ther. 2021;377(3):417–440. doi:10.1124/jpet.121.000567 · PMID 33727283

  5. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56(1):235–242. doi:10.1124/mol.56.1.235 · PMID 10385705

  6. Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1475–R1484. doi:10.1152/ajpregu.00703.2009 · PMID 20357016

  7. Boyle CN, Lutz TA, Le Foll C. Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203–210. doi:10.1016/j.molmet.2017.11.009 · PMID 29203236

  8. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. doi:10.1016/j.molmet.2020.101090 · PMID 32987188

Read more about peptides